Prasugrel Hydrochloride

A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.

Also Known As:

Networked: 1445 relevant articles (209 outcomes, 443 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Angiolillo, Dominick J: 61 articles (10/2022 - 12/2007)
2.	Jakubowski, Joseph A: 53 articles (01/2018 - 04/2005)
3.	Winters, Kenneth J: 42 articles (06/2017 - 06/2005)
4.	Alexopoulos, Dimitrios: 40 articles (10/2022 - 10/2011)
5.	Wiviott, Stephen D: 39 articles (01/2020 - 06/2005)
6.	Montalescot, Gilles: 38 articles (10/2022 - 10/2006)
7.	Kastrati, Adnan: 36 articles (09/2022 - 01/2012)
8.	Sibbing, Dirk: 32 articles (09/2022 - 09/2011)
9.	Roe, Matthew T: 31 articles (01/2020 - 01/2007)
10.	Xanthopoulou, Ioanna: 30 articles (08/2021 - 10/2011)

Related Diseases

1.	Hemorrhage 01/01/2022 - "Although early prasugrel was the best option to reduce most secondary cardiovascular outcomes, it was associated with the highest bleeding risk. " 01/01/2022 - "Low-dose prasugrel might be also beneficial in the chronic phase without increasing the bleeding risk among stable CAD patients in other countries." 12/01/2018 - "In Indian patients, 30 mg of prasugrel loading is as effective as 60 mg of prasugrel with significantly less minor bleeding." 11/01/2014 - "Prasugrel was found to be effective & not associated with a high incidence of bleeding in the high risk ACS patients when those at a high bleeding risk were excluded." 01/01/2013 - "Identification of factors affecting platelet reactivity (PR) and high PR (HPR) or high platelet inhibition (HPI) rates while on prasugrel maintenance dose (MD) might be helpful in avoiding ischemic or bleeding complications. "
2.	Acute Coronary Syndrome 02/01/2013 - "This CYP-mediated drug-drug interaction might lead to a significant reduction of prasugrel efficacy in HIV-infected patients with acute coronary syndrome." 02/01/2010 - "These pharmacodynamic properties led prasugrel to be more effective in preventing ischemic events in patients with acute coronary syndromes undergoing PCI in the setting of the recent TRITON-TIMI 38 study. " 04/01/2018 - "This early postmarketing observational study evaluated the safety and efficacy of short-term prasugrel use in patients with acute coronary syndrome (ACS) in real-world clinical settings in Japan. " 01/01/2018 - "Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes." 09/01/2013 - "Improved biological efficacy of prasugrel one month after an acute coronary syndrome."
3.	Myocardial Infarction 01/01/2021 - "In addition, we describe the design of an example target trial created to emulate the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial and compare effect estimates. " 06/01/2014 - "(Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38; NCT00097591)." 11/01/2013 - "Patients from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial (N = 13 608) with adjudicated ST classified per the Academic Research Consortium definitions of definite (N = 135) and probable (N = 27) were grouped into prespecified 8-hour intervals by time of onset: early (6 am-2 pm), late-day (2 pm-10 pm), and overnight (10 pm-6 am). " 04/01/2012 - "Decision model based on event occurrence in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38. " 01/31/2012 - "American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)."
4.	ST Elevation Myocardial Infarction 06/01/2013 - "Prasugrel is indicated in patients with ACS undergoing PCI and was most effective in diabetics and in patients with STEMI. " 02/01/2014 - "Our study demonstrates that prasugrel could produce a significantly greater peri-procedural as well as in-hospital IPA compared with TAP in patients with STEMI undergoing primary PCI." 07/01/2018 - "In STEMI patients, a significant reduction in PRU was observed at 4 h after prasugrel loading. " 01/01/2018 - "In this contemporary study of patients with STEMI, early prasugrel cessation was not uncommon and primarily involved change to another P2Y12-inhibitor. " 02/18/2014 - "The aim of this study was to determine whether response to prasugrel is associated with the proportion of circulating reticulated platelets (RPs) in patients with ST-segment elevation myocardial infarction (STEMI). "
5.	Stroke (Strokes) 01/01/2022 - "Network meta-analysis showed that prasugrel was associated with similar occurrence of the primary endpoint and of a secondary ischaemic endpoint (composite of MI and stroke) and was most likely the best treatment [Surface Under the Cumulative Ranking curve Analysis (SUCRA) 54.5 and 59.8, respectively]. " 04/03/2023 - "Three phase 3 trials (PRASTRO-I/II/III) were conducted to determine the efficacy of prasugrel in preventing recurrent stroke. " 02/01/2021 - "Although statistical significance was not reached, the efficacy of prasugrel was potentially different between stroke subtypes, warranting further studies." 05/01/2009 - "Managed care decision makers should consider specific criteria limiting prasugrel use to health plan members with characteristics similar to the study population in TRITON-TIMI 38 that benefited from treatment and avoiding use in patients with prior history of stroke or TIA. " 01/01/2023 - "For ischemic outcomes, including MI, stroke, and revascularization, prasugrel had the most favorable trend. "

Related Drugs and Biologics

1.	Clopidogrel (Plavix)
2.	Ticagrelor
3.	Aspirin (Acetylsalicylic Acid)
4.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
5.	thienopyridine
6.	bivalirudin (Angiomax)
7.	omega-Chloroacetophenone (Mace)
8.	cangrelor
9.	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
10.	Glycoproteins (Glycoprotein)

Related Therapies and Procedures

1.	Percutaneous Coronary Intervention
2.	Therapeutics
3.	Stents
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Drug Tapering